Although the authors noted in their paper that, because the analysis is post hoc, it’s primarily hypothesis generating, Dr. Khanna emphasizes some of the take-home messages for rheumatologists: “The post hoc analysis highlights, first, that patients with early ILD [don’t just have] mild ILD. Second, the effect of tocilizumab is consistent in those with mild to severe ILD. Third, the placebo group had a consistent decline, irrespective of the degree of ILD.”
Lara C. Pullen, PhD, is a medical writer based in the Chicago area.
ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
References
- Deyton CP, Khanna D. Systemic sclerosis. Lancet. 2017 Oct 7;390(10103):1685–1699.
- Bernstein EJ, Khanna D, Lederer DJ. Screening high resolution computed tomography of the chest to detect interstitial lung disease in systemic sclerosis: A global survey of rheumatologists. Arthritis Rheumatol. 2018 Jun;70(6):971–972.
- Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): A phase 2, randomized, controlled trial. Lancet. 2016. 387:2630–2640.
- Khanna D, Lin CJ, Furst DE, et al. Tocilizumab in systemic sclerosis: A randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020. 8:963–974.
- Roofeh D, Lin CJF, Goldin J, et al. Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol. 2021 Jul. 73(7):1301–1310.
